tbuckley/cabot-search huggingface dataset:
An Official American Thoracic Society Systematic Review: The Effect of Nighttime Intensivist Staffing on Mortality and Length of Stay among Intensive Care Unit Patients
Authors: Meeta Prasad Kerlin, Neill K. J. Adhikari, Louise Rose, M. Elizabeth Wilcox, Cassandra J. Bellamy, Deena Kelly Costa, Hayley B. Gershengorn, Scott D. Halpern, Jeremy M. Kahn, Meghan B. Lane-Fall, David J. Wallace, Curtis H. Weiss, Hannah Wunsch, Colin R. Cooke
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Section:ChooseTop of pageAbstract <<ContentsMethodsResultsDiscussionReferencesCITING ARTICLES
Genetic Polymorphisms Associated with Priapism in Sickle Cell Disease.
Authors: Laine Elliott, Allison E. Ashley-Koch, Jude Jonassaint, Jennifer Price, Jason Galloway, Kenneth I. Ataga, Marc C. Levesque, J. Brice Weinberg, James R. Eckman, Eugene P. Orringer, Jeffery M. Vance, Marilyn J. Telen
Journal: Blood (2006)
The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship
Authors: Marin H. Kollef, Matteo Bassetti, Bruno Francois, Jason Burnham, George Dimopoulos, Jose Garnacho-Montero, Jeffrey Lipman, Charles-Edouard Luyt, David P. Nicolau, Maarten J. Postma, Antonio Torres, Tobias Welte, Richard G. Wunderink
Journal: Intensive Care Medicine (2017)
Updated results of the FIRIS study: A phase II/III trial of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer (mCRC).
Authors: H. Baba, K. Muro, H. Yasui, Y. Shimada, A. Tsuji, S. Sameshima, T. Satoh, T. Denda, K. Ina, K. Sugihara
Journal: Journal of Clinical Oncology (2011)

3562 Background: The FIRIS study (Muro K et al. Lancet Oncol 2010;11:853–860) previously demonstrated the non-inferiority of IRIS to FOLFIRI, with progression-free survival (PFS) as the primary endpoint. We now report the final results of this study. Methods: The FIRIS study is a randomized, prospective, open-label, phase II/III study. Irinotecan (IRI)-naïve mCRC patients with one prior chemotherapy regimen, ECOG PS 0–1, and adequate organ function were randomized to receive either FOLFIRI (200 mg/m2 of l-leucovorin given simultaneously with 150 mg/m2 of IRI, followed by a 400 mg/m2 bolus of 5-FU on day 1, and then 2,400 mg/m2 of 5-FU over 46 h, every 2 weeks) or IRIS (125 mg/m2 of IRI on days 1 and 15, and 40–60 mg/body of S-1 twice daily for 2 weeks, followed by a 2-week rest). The primary endpoint was PFS. Secondary endpoints were overall survival (OS), response rate (RR), safety, and treatment cost. Patient information was updated in July 2010. Results: At this final analysis, median follow-up was 3.11 years. Median PFS was 5.1 months (95% CI: 4.2–6.0) in the FOLFIRI group and 5.8 months (95% CI: 4.5–6.0) in the IRIS group (adjusted HR=1.058, 95% CI: 0.869–1.289, p=0.022 for non-inferiority), which is consistent with earlier results (HR=1.077, 95% CI: 0.869-1.319, p=0.039). Median OS was 17.5 months (95% CI: 14.9–19.4) in the FOLFIRI group and 18.0 months (95% CI: 15.0-21.0) in the IRIS group (adjusted HR=0.901, 95%CI: 0.728-1.115 p=0.0003 for non-inferiority). In patients with prior oxaliplatin treatment, median OS was 15.3 and 13.3 months in the IRIS and FOLFIRI groups, respectively (adjusted HR=0.773, 95% CI: 0.593–1.007), whereas in patients without prior oxaliplatin treatment it was 23.6 and 26.9 months, respectively (adjusted HR=1.188, 95% CI: 0.833–1.694). Conclusions: The non-inferiority of IRIS to FOLFIRI, with PFS and OS as endpoints, is reconfirmed. Thus, IRIS can be an additional second line option for mCRC treatment.
Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients
Authors: Rui Wang, Jing Wang, Ge Gao, Juan Hu, Yuanyuan Jiang, Zhenlong Zhao, Xiaodong Zhang, Yu-Dong Zhang, Xiaoying Wang
Journal: Clinical Cancer Research (2017)

Purpose: To investigate whether prebiopsy multi-parametric (mp) MRI can help to improve predictive performance in prostate cancer.Experimental Design: Based on a support vector machine (SVM) analysis, we prospectively modeled clinical data (age, PSA, digital rectal examination, transrectal ultrasound, PSA density, and prostate volume) and mp-MRI findings [Prostate Imaging and Reporting and Data System (PI-RADS) score and tumor-node-metastasis stage] in 985 men to predict the risk of prostate cancer. The new nomogram was validated in 493 patients treated at the same institution. Multivariable Cox regression analyses assessed the association between input variables and risk of prostate cancer, and area under the receiver operating characteristic curve (Az) analyzed the predictive ability.Results: At 5-year follow-up period, 34.3% of patients had systemic progression of prostate cancer. Nomogram (SVM-MRI) predicting 5-year prostate cancer rate trained with clinical and mp-MRI data was accurate and discriminating with an externally validated Az of 0.938, positive predictive value (PPV) of 77.4%, and negative predictive value of 91.5%. The improvement was significant (P < 0.001) compared with the nomogram trained with clinical data. When stratified by PSA, SVM-MRI nomogram had high PPV (93.6%) in patients with PSA > 20 ng/mL, with intermediate to low PPV in PSA 10 to 20 ng/mL (64%), PSA 4 to 10 ng/mL (55.8%), and PSA 0 to 4 ng/mL (29%). PI-RADS score (Cox HR, 2.112; P < 0.001), PSA level (HR, 1.435; P < 0.001), and age (HR, 1.012; P = 0.043) were independent predictors of prostate cancer.Conclusions: Featured with low false positive rate, mp-MRI could be the first investigation of a man with a raised PSA before prostate biopsy. Clin Cancer Res; 23(14); 3692-9. ©2017 AACR.
Favorable Results After GCSF-Primed Allogeneic BMT for Children with Severe Aplastic Anemia Using Busulfan, Cyclophosphamide and ATG as Conditioning Regimen and Cyclosporine-A and Micofenolate Mofetil as Graft-Versus-Host-Disease Prophylaxys: Rapid Engraftment, Low Incidence of Chronic Gvhd and Reduced Graft Rejection Rates.
Authors: Mauricio Ostronoff, Fabiana Ostronoff, Rodolfo Calixto, Alexandre Sucupira, Manuela Gomes, Rodrigo Florencio, Monique Martins, ANA Patricia Souto Maior
Journal: Blood (2010)
Expression of Annexin 2 in Pediatric B-Acute Lymphoblastic Leukemia: A Marker of Aggressiveness and A Potential Therapeutic Target.
Authors: Manuela Tumino, Benedetta Accordi, Manuela Sciro, Gloria Milani, Federica Tognazzo, Marco Giordan, Truus Te Kronnie, Giuseppe Basso, Luca Lo Nigro
Journal: Blood (2009)
Insights into Diabetic Kidney Disease Using Urinary Proteomics and Bioinformatics
Authors: Julie A.D. Van, James W. Scholey, Ana Konvalinka
Journal: Journal of the American Society of Nephrology (2017)

A number of proteomic and peptidomic analyses of urine from diabetic subjects have been published in the quest for a biomarker that predicts progression of nephropathy. Less attention has been paid to the relationships between urinary proteins and the underlying biological processes revealed by the analyses. In this review, we focus on the biological processes identified by studying urinary proteins and protein-protein interactions at each stage of diabetic nephropathy to provide an overview of the events underlying progression of kidney disease reflected in the urine. In uncomplicated diabetes, proteomic/peptidomic analyses indicate that early activation of fibrotic pathways in the kidney occurs before the onset of microalbuminuria. In incipient nephropathy, when albumin excretion rates are abnormal, proteomic/peptidomic analyses suggest that changes in glomerular permselectivity and tubular reabsorption account, at least in part, for the proteins and peptides that appear in the urine. Finally, overt nephropathy is characterized by proteins involved in wound healing, ongoing fibrosis, and inflammation. These findings suggest that there is a spectrum of biological processes in the diabetic kidney and that assessing protein networks may be more informative than individual markers with respect to the stage of disease and the risk of progression.
Genetic Association Studies of Pain Phenotypes in Adult SCD Patients
Authors: Abdullah Kutlar, Leigh G Wells, Hongyan Xu, Latanya Bowman, Pritam Bora, Arati Rani Chand, Betsy Clair, Steffen E Meiler, Xiaoling Wang, Kavita Natrajan, Niren Patel, Roger B Fillingim
Journal: Blood (2014)
Age Is the Strongest Determinant of Leukemia Blast Cell Gene Expression in MLL-Rearranged Infant ALL and MLL-AF4 Directs a Distinct Gene Expression Profile Related to CNS Disease.
Authors: Blaine W. Robinson, Kajia Cao, Joanne M. Hilden, Patricia A. Dinndorf, Nyla A. Heerema, Harland N. Sather, Ron McGlennen, Stephen P. Hunger, Gregory H. Reaman, Li-San Wang, Carolyn A. Felix
Journal: Blood (2008)
Next Generation Transcriptomic Resequencing Identifies Novel Genetic Alterations in High-Risk (HR) Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) HR ALL TARGET Project.
Authors: Charles G. Mullighan, Ryan Morin, Jinghui Zhang, Martin Hirst, Yongjun Zhao, Chunhua Yan, Richard Finney, Michael Edmonson, Xiaoping Su, Kenneth E Buetow, William L. Carroll, I-Ming Chen, Meenakshi Devidas, Daniela Gerhard, Richard C. Harvey, Ying Hu, Mignon L. Loh, Gregory Reaman, Mary V. Relling, Malcolm A. Smith, James R. Downing, Stephen P Hunger, Cheryl L. Willman, Marco Marra
Journal: Blood (2009)
A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod (TASQ) in patients (pts) with mCRPC responsive to or stabilized during first-line docetaxel chemotherapy.
Authors: Karim Fizazi, Albertas Ulys, Lisa Sengeløv, Mette Moe, Sylvain Ladoire, Antoine Thiery- Vuillemin, Aude Flechon, Roberto Sabbatini, Joaquim Bellmunt, Miguel Angel Climent, Simon Chowdhury, Herlinde Dumez, Michaela Matouskova, Nicolas Penel, Sigita Liutkauskiene, Lech Stachurski, Cora N. Sternberg, Frederique Baton, Nathalie Germann, Gedske Daugaard
Journal: Journal of Clinical Oncology (2016)

201 Background: TASQ is an oral immunomodulatory, antiangiogenic and antimetastatic agent that targets the tumor microenvironment. In a phase 2 trial in mCRPC, TASQ increased PFS in chemotherapy-naive pts vs placebo (PBO) (Pili et al. JCO 2011), but there was no OS benefit in a recent phase 3 trial (NCT01234311). This study assessed whether TASQ maintenance therapy improved disease control duration in mCRPC pts with response or stabilization on first-line docetaxel (NCT01732549). Methods: Pts with mCRPC not progressing after docetaxel (min. 6 cycles; RECIST criteria; no PSA rise for last 3 tests) were assigned (1:1) to receive within 6 wks of last docetaxel administration: oral TASQ qd (0.25 mg/d rising to 1.0 mg/d over 4 wks, if tolerated) or PBO, until progression or toxicity. Randomization was stratified by visceral metastases and opioid analgesic use. Primary endpoint: radiographic PFS (rPFS) per RECIST 1.1 and PCWG 2 criteria, assessed locally. Planned sample size: 140 pts to achieve 80% power to detect an rPFS hazard ratio (HR) of 0.588 with a 1-sided α error of 0.05. Secondary endpoints: other clinical outcome measures, OS and safety. Results: From Jan 2013 to Oct 2014, 144 pts were randomized (TASQ: n = 71; PBO: n = 73) at 44 sites in 11 countries. Baseline characteristics were similar in both groups – median age: 70 yrs; visceral metastases: 23%; ECOG PS 0–1: 97%; opioid use: 15%. Median follow up: 59 wks for TASQ; 53 wks for PBO. Median rPFS (locally assessed) was 31.7 wks [90% CI 24.3–53.7] with TASQ; 22.7 wks [90% CI 16.1–25.9] with PBO (HR 0.6 [90% CI 0.4–0.9]; p = 0.0162). OS data are immature (14 deaths). Median time to next anticancer therapy: 42.3 wks [90% CI 32.0–58.0] for TASQ; 29.0 wks [90% CI 23.1–39.1] for PBO (HR 0.7 [90% CI 0.5–1.0]). TEAEs ( ≥ Grade 3): TASQ (51%); PBO (26%). TEAEs with TASQ (all grades; &gt; 20%): decreased appetite (37%), constipation (32%), fatigue (28%), nausea (27%), arthralgia (25%), asthenia (24%) and back pain (21%). Conclusions: We believe this is the first completed trial of a maintenance strategy with a novel agent in mCRPC, an appealing concept in pts not progressing after docetaxel therapy. Clinical trial information: NCT01732549.
PTU-021 Occult vs. overt upper gastrointestinal bleeding – inverse relationship and the use of mucosal damaging and protective drugs: Abstract PTU-021 Table 1
Authors: AS Taha, C McCloskey, T Craigen, A Simpson, WJ Angerson
Journal: Gut (2015)

<h3>Introduction</h3> Efforts have been focused on the prevention of overt upper gastrointestinal bleeding (UGIB), using acid inhibitors, particularly in users of NSAIDs and anti-thrombotic therapy (ATT). Little is known about the impact of such efforts on occult GIB which might also originate from sites not protected by acid inhibition. We aimedto measure the incidence of both overt and occult GIB in a well-defined geographical region over a 5-year period, 2007–2012; assess the use of NSAIDs, ATT, PPIs, and iron therapy; and compare the outcomes of patients with occult vs. overt GIB. <h3>Method</h3> The incidence was analysed in 2007, 2010 and 2012. Overt UGIB included haematemesis and melena. A sample of 300 patients (100 from each of the 3 index years) with occult GIB was randomly selected and their outcomes and details were compared with those of patients with overt UGIB (N = 869) using the Mann-Whitney and Fisher’s exact tests. Trends with time in incidence were assessed using the chi-squared test for trend. Numbers of prescriptions issued per 1000 population were recorded for each year from 2007 to 2012 and trends were assessed using Pearson correlation analysis. <h3>Results</h3> The incidence of overt UGIB and occult GIB and details of drug use are shown in Table 1. Demography: Compared with patients with occult GIB (N = 300) randomly selected in the 3 index years, those with overt UGIB (N = 869) had a median (IQR) age of 63 (47–77) years vs. 67 (53–75) in the occult group (NS), 62.5% males vs. 39.3% (P &lt; 0.001), 33.3% smokers vs. 28.0% (NS), and 25.0% excessive alcohol drinkers vs. 11.0% (P &lt; 0.001), respectively. Both groups were comparable in the use of NSAIDs and ATT, but overt UGIB patients had higher Charlson comorbidity scores, 2 (1–3) vs. 1 (0–2) (P &lt; 0.001). Transfusion and 30-day mortality: 3.8% in the overt UGIB group died vs. 3.0% (NS) in the occult group, and 34.3% vs. 13.0% (P &lt; 0.001) were transfused with 3 (2–6) blood units vs. 2.5 (2–4) (P = 0.024), respectively in the occult GIB group. <h3>Conclusion</h3> (1) The incidence of occult GIB continues to rise while that of overt UGIB continues to fall. (2) This is accompanied by a rise in the use of NSAIDs, PPIs, and iron therapy. (3) Patients with occult GIB have similar 30-day mortality to overt UGIB but are less likely to require blood transfusion. (4) An alternative approach to acid inhibition might be needed to prevent occult GIB. <h3>Disclosure of interest</h3> None Declared.
Argentine Registry of Hematologic Disease (RAEH) Chronics Myeloid Leukemia
Authors: Alicia Inés Enrico, Beatriz Moiraghi, Graciela Klein, Maria del Rosario Cabrejo, Renee Crisp, Georgina Bendek, Mariana Gil, Juan Garcia, Abel Alzueta, Alejandro Cicchetti, Francisca Rojas, Mariel Perez, Ruben Burgos, Raquel Bengió
Journal: Blood (2011)
Combined aCGH and Mutational Analysis of CLL Patients with 17p Deletion.
Authors: Hannah C. Rudenko, Vasantha Brito-Babapulle, David Gonzalez, Pilar Martinez, Paola E. Leone, Chris Jones, Tim Dexter, Kerry Fenwick, Alan Mackay, Alan Ashworth, Estella Matutes, Daniel Catovsky, Claire Dearden, Gareth J. Morgan
Journal: Blood (2006)
Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.
Authors: Kami Maddocks, Rosa Lapalombella, Kristie A Blum, William Blum, Beth B. Fischer, Natarajan Muthusamy, Mollie E. Moran, Donna Holtzapfel, John C. Byrd, Amy J. Johnson, Leslie Andritsos
Journal: Blood (2009)
Methylation of a Single CpG in the GADD45A Proximal Promoter Is Associated with Poor Survival in Acute Myeloid Leukemia,
Authors: Richard J D'Andrea, Michelle Perugini, Chung H Kok, Diana Salerno, Silke Danner, Peter G Bardy, Andrew H Wei, L. Bik To, Ian D Lewis
Journal: Blood (2011)
Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy
Authors: Carlos Alberto Fajardo, Sonia Guedan, Luis Alfonso Rojas, Rafael Moreno, Marcel Arias-Badia, Jana de Sostoa, Carl H. June, Ramon Alemany
Journal: Cancer Research (2017)

Abstract Antiviral immune responses present a major hurdle to the efficacious use of oncolytic adenoviruses as cancer treatments. Despite the existence of a highly immunosuppressive tumor environment, adenovirus-infected cells can nonetheless be efficiently cleared by infiltrating cytotoxic T lymphocytes (CTL) without compromising tumor burden. In this study, we tested the hypothesis that tumor-infiltrating T cells could be more effectively activated and redirected by oncolytic adenoviruses that were armed with bispecific T-cell–engager (BiTE) antibodies. The oncolytic adenovirus ICOVIR-15K was engineered to express an EGFR-targeting BiTE (cBiTE) antibody under the control of the major late promoter, leading to generation of ICOVIR-15K-cBiTE, which retained its oncolytic properties in vitro. cBiTE expression and secretion was detected in supernatants from ICOVIR-15K-cBiTE–infected cells, and the secreted BiTEs bound specifically to both CD3+ and EGFR+ cells. In cell coculture assays, ICOVIR-15K-cBiTE–mediated oncolysis resulted in robust T-cell activation, proliferation, and bystander cell-mediated cytotoxicity. Notably, intratumoral injection of this cBiTE-expressing adenovirus increased the persistence and accumulation of tumor-infiltrating T cells in vivo, compared with the parental virus lacking such effects. Moreover, in two distinct tumor xenograft models, combined delivery of ICOVIR-15K-cBiTE with peripheral blood mononuclear cells or T cells enhanced the antitumor efficacy achieved by the parental counterpart. Overall, our results show how arming oncolytic adenoviruses with BiTE can overcome key limitations in oncolytic virotherapy. Cancer Res; 77(8); 2052–63. ©2017 AACR.
Long-Term Follow-Up of Treatment Outcome and Prognosis in 96 Chinese Children with Acute Myeloid Leukemia: A Single Center Experience.
Authors: Yongmin Tang, Xiaojun Xu, Hua Song, Shilong Yang, Shuwen Shi, Jian Wei, Weiqun Xu, Binhua Pan, Yinghu Chen, Fenying Zhao, Hongqiang Shen, Baiqin Qian, Linyan Zhang, Botao Ning
Journal: Blood (2006)
Toxicity-adjusted dose (TAD) administration of chemotherapy: Effect of baseline and nadir neutrophil count in patients with breast, ovarian, and lung cancer?
Authors: A. Carus, F. Donskov, V. Gebski, R. Kefford, N. Wilcken, R. Hui, P. R. Harnett, M. Ladekarl, H. von der Maase, H. Gurney
Journal: Journal of Clinical Oncology (2011)

e21023 Background: In some solid cancers a survival benefit has been observed for patients who had chemotherapy-induced neutropenia. The prognostic impact of baseline and nadir blood neutrophils was assessed in the present study. Methods: Data on patients with breast cancer st.I-IV, ovarian cancer st.I-IV, non-small cell lung cancer (NSCLC) st.II-IV, and small-cell lung cancer (SCLC) treated from 1997 to 2005 at Westmead Hospital, Sydney, with complete medical records of the first 3 cycles of chemotherapy and a full set of baseline and nadir laboratory data were collected from patient medical files.Survival data were updated 2010. Results: A total of 819 patients were identified, comprising 507 patients with breast cancer, 118 patients with ovarian cancer, 115 patients with NSCLC and 79 patients with SCLC. Median survival for ovarian cancer patients obtaining nadir neutropenia below 2.0 x 109/l was 56 months. In contrast, median survival for ovarian cancer patients who had nadir neutropenia above 2.0 was 27 months. In a multivariate analysis, adjusting for well-known prognostic features, nadir neutropenia below 2.0 was statistically significant (HR 1.73;p=0.03). In patients with NSCLC, baseline elevated neutrophil count was associated with short survival (p< 0.00001). The subgroup of NSCLC patients with baseline neutrophils above median value (5.9) had significantly improved survival if they obtained nadir neutropenia below 2.0 (median survival 13.4 vs 8.8 mo, p=0.041). On the contrary, in the subgroup of NSCLC patients with baseline neutrophils below median value, nadir neutropenia did not impact survival. Finally, no impact of nadir neutropenia on survival was observed for SCLC or breast cancer patients. Conclusions: Chemotherapy-induced nadir neutropenia was significantly associated with improved overall survival in patients with ovarian cancer and the subgroup of NSCLC with baseline elevated neutrophils, whereas no significant impact was observed in small cell lung cancer or breast cancer in this cohort of patients. The prognostic impact of nadir neutropenia in ovarian and non small cell lung cancer should be confirmed in larger prospective trials.
Targeting NCAM-expressing neuroblastoma with polymeric precision nanomedicine
Authors: Ela Markovsky, Anat Eldar-Boock, Dikla Ben-Shushan, Hemda Baabur-Cohen, Eilam Yeini, Evgeni Pisarevsky, Ariel Many, Sarit Aviel-Ronen, Iris Barshack, Ronit Satchi-Fainaro
Journal: Journal of Controlled Release (2017)
Lenalidomide and Dexamethasone Combination in Patients with Chronic Lymphocytic Leukemia (CLL) Relapsing or Resistant to Treatment (LENDEX-LLC-09): A Gene Expression Profiling Study
Authors: Anna Puiggros, Pau Abrisqueta, Lara Nonell, Marta Bodalo, Eulalia Puigdecanet, María José Terol, Julio Delgado, Lourdes Escoda, Gonzalo Blanco, Sergi Serrano, Francesc Bosch, Blanca Espinet
Journal: Blood (2014)
Monitoring small airways disease (SAD) in cystic fibrosis (CF)
Authors: Iris Groothuis, S. Lever, K. Gonzalez Graniel, L. Tepper, E.M. Nieuwhof, E. van der Wiel, J. Kok-van der Weijde, Hawm Tiddens
Journal: European Respiratory Journal (2011)

Introduction: CF lung disease starts in small airways. SAD is visible on chest-CT as trapped air (TA). For routine monitoring of CF lung disease spirometry parameters are used. Forced expiratory flow after 75% of vital capacity is exhaled (FEF75) is a sensitive marker of SAD. Lung Clearance Index (LCI) obtained by Multiple Breath Washout test (MBW) has been advocated as a parameter to monitor SAD. Whether LCI is more sensitive than FEF75 to detect SAD is unknown.

Aims: To study the relation between FEF75 and LCI and trapped air on CT and between FEF75 and LCI.

Methods: Retrospective study of stable CF patients (n=50) who had their (bi)-annual check-up including chest-CT and spirometry. Tidal breathing MBW (n=23) was performed using the Ecomedics Exhalyzer D. In- and expiratory (volumetric) chest CT-scans were scored using the CF-CT score and expressed as% of maximum score.

Results: CF patients (1-19 years, male N=26). 36% had chronic pseudomonas. FEF75 mean 45,5 (range 7,5-119,2)% predicted, LCI 9,4 (6,9-14,3), TA 33,0 (0-83,3)% FEF75 correlated with LCI (N=23) (r=0,573, p=0,005). FEF75 (n=49) correlated with bronchiectasis (r=0,339, p=0,016), airwall thickening (r=0,520, p<0,001), mucusplugging (r=0,505, p <0,001) parenchymal abnormalities (r=0,508, p<0,001) and total CF-CT score (r=0,535, p <0,001) but not with TA. LCI did not correlate with abnormalities on CT.

Conclusion: FEF75 correlates with LCI. Neither FEF75 nor LCI correlate with TA. The additional value of LCI over FEF75 as a sensitive monitoring tool for SAD requires further validation.
Genes Important for Disease Progression of MDS-Leukemia Revealed by 40K cDNA Microarray.
Authors: Hiroshi Miwa, Hidemi Teramoto, Vyomesh Patel, Noah Letwin, Maria D. Castellone, Norikazu Imai, Masato Shikami, Akira Imamura, Silvio Gutkind, Masakazu Nitta, Norman H. Lee
Journal: Blood (2005)
Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant
Authors: Prashant Hiwarkar, Persis Amrolia, Ponni Sivaprakasam, Su Han Lum, Hemalatha Doss, Ciara O’Rafferty, Toni Petterson, Katharine Patrick, Juliana Silva, Mary Slatter, Sarah Lawson, Kanchan Rao, Colin Steward, Adam Gassas, Paul Veys, Robert Wynn
Journal: Blood (2017)